Search Immortality Topics:

Page 11«..10111213..2030..»


Category Archives: Stem Cell Therapy

Life-Saving Innovations in Cancer-Fighting Stem Cell Transplants and Pioneering Research in HIV, Autism and Cerebral Palsy to be Featured at World…

On November 15th, World Cord Blood Day 2022 celebrations will be held around the globe (free online medical conference and educational events worldwide open to the public). Learn how cord blood is used to treat 80+ life-threatening diseases including many blood cancers and holds tremendous potential in the treatment of HIV, autism and cerebral palsy.

TUCSON, Ariz., Sept. 14, 2022 /PRNewswire/ -- We are pleased to announce World Cord Blood Day 2022 (WCBD 2022) will take place on November 15th, featuring a free online medical conference and educational events worldwide. This year's official online conference will highlight innovations in cancer-fighting stem cell transplants using cord blood, as well as ground-breaking cord blood research and novel cell therapies in the potential treatment of HIV, autism, cerebral palsy and more.

Cord blood is the blood left in the umbilical cord and placenta following the birth of a child. It is rich in life-saving stem cells. If collected and stored properly, these cells can be used in stem cell transplants to treat over 80 life-threatening diseases including leukemia, lymphoma, and thalassemia to name a few.

Since 1988, more than 40,000 cord blood transplants have been performed worldwide. Yet, cord blood is still thrown away as medical waste in the majority of births. Education is key to changing this practice and World Cord Blood Day 2022 will provide the perfect opportunity for OBGYNs, midwives, transplant doctors, nurses, parents, students and government authorities to learn about this vital medical resource.

Organized by Save the Cord Foundation, a 501c3 non-profit, World Cord Blood Day 2022 is officially sponsored by QuickSTAT Global Life Science Logistics, recognized leader in medical shipping and healthcare logistics. Inspiring Partners for this event include the Be the Match (NMDP), World Marrow Donor Association (WMDA-Netcord), Association for the Advancement of Blood and Biotherapies (AABB), Cord Blood Association, and the Foundation for the Accreditation of Cellular Therapy (FACT).

In addition to the many live events being held globally by WCBD Community Champions, a Facebook livestream will launch the official WCBD 2022 conference at 10am ET on November 15th. The full conference will be available to view on-demand via Eventbrite until December 15th (free, open to the public, registration required). New this year, a roundtable discussion will be held post-conference via LinkedIn (details coming soon) providing an opportunity for further exploration of session topics.

Visit http://www.WorldCordBloodDay.org to register free for the online conference and learn how you can participate on-line or at an event locally in your community (#WCBD22 #WorldCordBloodDay).

About Save the Cord Foundation (Organizer and host of WCBD 2022)

Save the Cord Foundation (a 501c3 non-profit) was established to advance cord blood education. The Foundation provides non-commercial information to parents, health professionals and the public regarding methods for saving cord blood, as well as current applications using cord blood and the latest research. Learn more at http://www.SaveTheCordFoundation.org.

About QuickSTAT Global Life Science Logistics (Official Sponsor of WCBD 2022)

Every day, QuickSTAT, a part of Kuehne+Nagel, safely and reliably moves thousands of critical shipments around the world. For over forty years, QuickSTAT has been entrusted with transporting human organs and tissue for transplant or research, blood, blood products, cord blood, bone marrow, medical devices, and personalized medicine, 24/7/365. QuickSTAT's specially trained experts work with hospitals, laboratories, blood banks and medical processing centers, and utilize the safest routes to ensure integrity, temperature control and chain of custody throughout the transportation process. Learn more at http://www.quickstat.aero.

Media Contact:Charis Ober(520) 419-0269[emailprotected]

SOURCE Save the Cord Foundation

Follow this link:
Life-Saving Innovations in Cancer-Fighting Stem Cell Transplants and Pioneering Research in HIV, Autism and Cerebral Palsy to be Featured at World...

Posted in Stem Cell Therapy | Comments Off on Life-Saving Innovations in Cancer-Fighting Stem Cell Transplants and Pioneering Research in HIV, Autism and Cerebral Palsy to be Featured at World…

Cell Therapy Technologies Markets, 2027 – Emergence of IPSCs as Alternatives to ESCs & Increased Focus on Personalized Medicine -…

DUBLIN--(BUSINESS WIRE)--The "Cell Therapy Technologies Market by Product (Media, Sera & Reagents, Cell Culture Vessels, Single Use Equipment, Systems & Software), Process (Cell Processing), Cell Type (T-cells, Stem Cells), End User (Biopharma, CMOs), Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

The cell therapy technologies market is projected to reach USD 8.0 Billion by 2027 from USD 4.0 Billion in 2022, at a CAGR of 14.6%

The growth can be attributed to the increasing public-private partnerships. Several government and private organizations have made significant investments to strengthen R&D in cell therapy leading to a surge in cell therapy technologies demand, hence propelling market growth.

Cell therapy instruments and consumables are used in the development of novel cell therapies for the treatment of different diseases and the mass production of cells from given samples or tissues.

Cell therapy technologies find major applications in regenerative medicine, stem cell research, cancer research, and cell biology research. These technologies are also extensively used in research centers and research institutes for life science and biopharmaceutical R&D.

The rising government investments in cell-based research, increasing incidence of chronic and infectious diseases, a large number of oncology-related cell therapy clinical trials, and increasing GMP certifications for cell therapy production facilities are the key factors driving the growth of this market.

The cell preservation and distribution and handling process segment accounted for the second largest share of the market in 2021.

Cell preservation and distribution is an essential and vital step in the cell scaling-up process. In addition, with the growth in the demand for cell-based medical products and therapies, the demand for reliable storage equipment to preserve finite cell lines and cells manufactured in excess is expected to increase. This factor is expected to drive the growth of this market segment.

The CROs and CMOs accounted for the second largest share of the cell therapy technologies market in 2021.

To cater the large demand, pharmaceutical companies need to speed up clinical timelines, maintain business continuity, and free up resources for projects. This has increased outsourcing analytical tests to CROs and CMOs, thereby boosting the segment market growth.

Asia Pacific: The fastest-growing region in the cell therapy technologies market.

The Asia Pacific market is expected to register the highest CAGR during the forecast period. Some of the major factors contributing to the growth of the Asia Pacific market are low-cost manufacturing advantage, increasing per capita income, and the growing need to curb cancer. In addition, the growth of the geriatric population is also fueling the cell therapy technologies market in the region.

Premium Insights

Market Dynamics

Drivers

Restraints

Opportunities

Challenges

Patent Analysis

Company Profiles

Key Players

Other Players

For more information about this report visit https://www.researchandmarkets.com/r/2wd9fd

View original post here:
Cell Therapy Technologies Markets, 2027 - Emergence of IPSCs as Alternatives to ESCs & Increased Focus on Personalized Medicine -...

Posted in Stem Cell Therapy | Comments Off on Cell Therapy Technologies Markets, 2027 – Emergence of IPSCs as Alternatives to ESCs & Increased Focus on Personalized Medicine -…

CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data to be Presented at Heart Failure Society of America Annual Meeting -…

Sunnyvale, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc.[Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announcesthat new data from its CardiAMP Cell Therapy for Heart Failure pivotal trial (ClinicalTrials.gov Identifier: NCT02438306), will be presented at the Heart Failure Society of America (HFSA) Annual Meeting on October 1, 2022 at 6:00pm titled, Autologous Cell Therapy For HFrEF: Efficacy Outcomes at Two Years for The Roll-in Cohort of a Phase III Pivotal Trial. This years HFSA meeting provides a hybrid format; in-person at the Gaylord National Harbor in Washington, D.C., or global live on-line access.

This data from the CardiAMP Cell Therapy Heart Failure trial will be released Monday, October 3, 2022, with anticipated details for a conference call with trial clinical leadership and management to follow. The planned conference call is expected to review the data presented at the Heart Failure Society of America meeting, detail the status of the trial, and discuss efforts being taken to implement an adaptive statistical analysis plan as recommended by the recent independent Data Safety Monitoring Board (DSMB) review.

We look forward to presenting the two-year roll-in cohort results from the CardiAMP Cell Therapy for Heart Failure Trial at this years HFSA annual meeting, stated BioCardias Vice President of Clinical, Debby Holmes-Higgin. In addition, we look forward to detailing efforts towards the implementation of the adaptive statistical analysis plan, which may further reduce trial risk and enable the DSMB to review the data early for efficacy.

About BioCardiaBioCardia, Inc., headquartered in Sunnyvale, California, is a developer of two biotherapeutic platforms the CardiAMPautologous bone marrow derived mononuclear cell therapy for cardiovascular indications, and the NK1R+ allogenic bone marrow derived mesenchymal stem cell therapies for cardiovascular and pulmonary diseases. These platforms underlie four product candidates, each with the potential to meaningfully benefit millions of patients. Three of these investigational therapies are enabled by the Companys proprietary biotherapeutic delivery platforms, which the Company also selectively licenses to other biotherapeutic development firms.

Forward Looking Statements:This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to the presentation of data from the CardiAMP Heart Failure Trial and future conference calls. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.

We may use terms such as believes, estimates, anticipates, expects, plans, intends, may, could, might, will, should, approximately or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardias Form 10-K filed with the Securities and Exchange Commission on March 29, 2022, under the caption titled Risk Factors. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Media Contact:Anne Laluc, MarketingEmail:alaluc@biocardia.comPhone: 650-226-0120

Investor Contact:David McClung, Chief Financial OfficerEmail:investors@biocardia.comPhone: 650-226-0120

Read the original:
CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data to be Presented at Heart Failure Society of America Annual Meeting -...

Posted in Stem Cell Therapy | Comments Off on CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data to be Presented at Heart Failure Society of America Annual Meeting -…

How WhiteLab Genomics is using AI to aid gene and cell therapy development – TechCrunch

French biotech company WhiteLab Genomics has raised $10 million in funding for an AI platform designed to aid the discovery and development of genomic therapies.

Founded out of Paris in 2019, recent Y Combinator (YC) graduate WhiteLab Genomics provides gene and cell therapy companies with predictive software simulations to expedite the design of gene and cell therapies. Gene therapy, for the uninitiated, is an emerging treatment that involves replacing missing or defective genes in cells to correct genetic disorders, while cell therapy is about altering a cell or sets of cells to trigger an effect throughout the body.

Thousands of diseases, including cystic fibrosis, Parkinsons and Alzheimers stem from flaws in an individuals DNA, and emerging research in gene and cell therapies may eventually treat such conditions at their source, supplanting the need for drugs or surgery.

However, such therapies are typically costly to develop with no guarantee that theyll work. Current methodologies in developing new gene and cell therapies typically involves a trial-and-error approach, according to WhiteLab Genomics CEO and co-founder David Del Bourgo, whereby scientists make a scientific hypothesis and test it in a lab: if successful, it progresses to the next stage, but if its unsuccessful, they go back to square one with a different hypothesis. And this is where WhiteLab Genomics enters the fray, with a computational approach that meshes machine learning and deep learning techniques to process multiple scientific hypotheses at once, looking at different genetic variants to predict the best molecular design for the therapy based on the objectives.

Gene and cell therapies still suffer from poor efficacy, immunological secondary effects and very high development cost, Del Bourgo explained to TechCrunch. We provide customers with exhaustive predictive models combining genetics and computational biology in order to design and select the top candidates to be tested in the lab.

WhiteLab Genomics founders: CEO David Del Bourgo and Chief Science Officer Julien Cottineau. Image Credits: WhiteLab Genomics

As with just about any AI models, WhiteLab Genomics uses myriad datasets to train its algorithms spanning genomic, RNA, oncologic and protein repositories, in addition to an exhaustive set of documentation such as public scientific and clinical research data.

We also partner with specialized institutions to enrich the models with additional non-public data, Del Bourgo added. We train and validate our algorithms on well-characterized datasets that are interconnected within our Knowledge Graph Database. These included public databases, proprietary data and datasets from our partners. It predicts biological features from new genetic sequences to build new therapeutic vectors and generates new therapeutic constructs.

In terms of the kinds of treatments WhiteLab Genomics is helping to develop, Del Bourgo said that the company is currently working on projects including DNA-based therapies for metabolic conditions such as lysosomal diseases, as well as cell stem therapies for blood diseases such as sickle cell disease and immuno-gene therapies to treat cancers.

Elsewhere, anumber of companies are using AI to aid drug discovery, such as BenevolentAI, which has raised sizeable investments from the VC world, while theres TechCrunchs Startup Battlefield winner Cellino, which recently raised $80 million to develop cell therapies using AI. WhiteLab Genomics is similar, but its working with both gene and cell therapy companies.

Its also worth noting that WhiteLab Genomics represents a growing roster of French startups to successfully infiltrate the YC ranks. Of the 40 European companies in WhiteLab Genomics Winter 22 cohort, five were French, a figure that rose to eight of 34 for the Summer 22 tranche the second highest number from the whole of Europe.

With $10 million in the bank from French investor Omnes Capital and biopharmaceutical heavyweight Debiopharm, WhiteLab Genomics is now well-financed to build out its platform and double-down on its partnerships with the scientific realm, which so far has included notable collaborations with the French National Institute of Health and Medical Research (Inserm) and Genethon Laboratories, among other pharmaceutical and biotech companies.

Here is the original post:
How WhiteLab Genomics is using AI to aid gene and cell therapy development - TechCrunch

Posted in Stem Cell Therapy | Comments Off on How WhiteLab Genomics is using AI to aid gene and cell therapy development – TechCrunch

Advanced cellular therapy brings hope to KSA cancer patients – Omnia Health Insights

Cancer remains a major public health and economic burden on patients, families, and healthcare systems. But breakthrough advances in cancer biology in the last two decades have dramatically changed our understanding of its pathogenesis and, consequently, our strategies to beat it.

The progress in managing blood cancers, specifically lymphoma, has raised optimism in the medical community. Lymphomas are a diverse group of cancers that affect the lymphatic system and are one of the most common malignancies worldwide and in Saudi Arabia. They are histologically categorized into Hodgkin's lymphoma and non- Hodgkin's lymphoma (NHL), where each category has many subtypes.

Related: Pregnancy-associated breast cancer: How common is it?

Until the late 1990s, all we had in our battle against cancer were conventional treatment methods with surgery, radiation, and chemotherapy. With the more advanced medical tools at our disposal, drug development and discovery have shifted toward personalised cancer treatment with molecular and immunological targeted agents.

A good example is chimeric antigen receptor T-cell (CAR T-cell) therapy, a revolutionary approach for treating different haematologic malignancies, including NHL, acute lymphoblastic leukemia, and multiple myeloma. The currently available CAR T-cell therapies are genetically engineered autologous T lymphocytes with an enhanced immune response against a specific tumour antigen, CD19 in the case of NHL.

Related: HIPEC increases cancer survival rates but lacks regional awareness

The introduction of anti-CD19 CAR T-cell therapies to the market has given new hope to patients with refractory and relapsed aggressive B-cell lymphomas who progressed despite multiple prior treatments. This represents a paradigm shift in NHL treatment, where it induced an impressive response rate of 82 per cent in ZUMA-1 study with a five-year overall survival rate of 43 per cent and a 63.1-month median follow up. This encouraged the medical community to explore other ways to optimise the clinical impact of CAR-T cell therapy by studying how to integrate it with allogeneic hematopoietic stem cell transplantation or checkpoint blockade in the future.

More promising new innovative cellular therapeutics are on the future horizon for cancer patients, such as "off-the-shelf" or allogeneic CAR-T cell and CAR natural killer cell-based immunotherapy. This type of treatment may eventually replace conventional chemotherapy, which is the standard of care for patients with advanced stage Diffuse Large B Cell Lymphoma (DLBCL) for the past 20 years. While the addition of rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in 2010 has shown significant benefit over CHOP in all categories of older patients, only about two-thirds of patients are typically cured with R-CHOP in the first-line setting. Many clinical trials over the past years have evaluated different ways to improve R-CHOP outcomes with no luck.

Furthermore, there is a huge unmet need for effective treatment options in refractory and relapsed DLBCL. The prognosis of these patients is generally poor, where only 30 per cent to 40 per cent of patients will respond to chemotherapy.

Additionally, the safety of intense chemotherapy regimens for the treatment of NHL is a significant concern, especially in older, frail patients with other comorbidities. This becomes a challenge, as we know that survival of lymphoma patients is correlated with achievement of complete remission; hence, dose reductions could compromise the treatment outcomes. A recent challenge we have been facing regionally and globally is the shortage of essential conventional chemotherapy agents. This has led to treatment delays or treating urgent cases with suboptimal alternative chemotherapy regimens.

Any progress in diagnosing and treating lymphoma is welcome news in Saudi Arabia, where NHL is ranked as the second most common cancer type in Saudi men and fifth among Saudi women (Source: Saudi Cancer Registry, 2016). The median age of diagnosis is 50 years in males compared to 57 years in females, which is remarkably younger than the reported median age of diagnosis in the U.S.

Diffuse Large B Cell Lymphoma is the most common subtype of NHL, where it accounts for half of NHL cases in both genders among the Saudi population. More than 40 per cent of DLBCL cases present with an advanced-disease stage, which is associated with a lower survival rate. This delay in seeking medical attention could be explained by the lack of public awareness about the disease, especially since the clinical presentation includes unspecific symptoms, in addition to the absence of effective screening methods for early detection.

An important note to consider is that the local literature reporting lymphoma in Saudi Arabia is limited, as the reported data may not represent lymphoma epidemiology in the Kingdom. More data are needed, especially from peripheral hospitals.

Cancer management is complex, and various medical professionals play a critical role in the overall patient journey. As pharmacists, our responsibilities in CAR-T cell therapy programmes include policy development, clinical assessment of bridging and lymphodepleting chemotherapy, toxicity management, and patient and staff education. Pharmacists with an experience in cellular therapy are highly needed in clinical practice, as this treatment modality continues to evolve to effectively treat incurable haematologic malignancies and potentially even solid tumours.

Go here to read the rest:
Advanced cellular therapy brings hope to KSA cancer patients - Omnia Health Insights

Posted in Stem Cell Therapy | Comments Off on Advanced cellular therapy brings hope to KSA cancer patients – Omnia Health Insights

The Biggest CGT Breakthroughs Through the Eyes of Our 2022 Power List – The Medicine Maker

The relatively short history of cell and gene therapy is not lacking in dramatic moments. A previous outlier, this vibrant field now represents the next great hope and so, when roadblocks to progress are removed or even lowered, theres reason to celebrate. Here, seven members of The Medicine Maker Power List 2022, reflect on the most impactful cell and gene milestones.

There have been many significant breakthroughs in cell and gene therapy over the past few years. Specifically in gene-modified cell therapy, the CAR T story is remarkable. Over the past several years, multiple autologous CAR T therapies have been successfully translated from bench to bedside and received marketing authorization as potentially curative therapies for patients with recalcitrant cancer indications: Kymriah and Yescarta for treating r/r/ ALL, MCL, and LBCL, and Abecma for treating r/r multiple myeloma.

Equally impressive in gene therapy, Zolgensma, an AAVSMN1 gene replacement product, has been developed for use as a one-time gene replacement treatment for infants with spinal muscular atrophy (SMA). The 15 year follow-up study these tiny patients are enrolled in after treatment will inform us on the long-term safety and efficacy of gene replacement therapy.

These products have been translated by academia and SMEs and partnered for advanced development with pharma to achieve both medical and commercial success.

The biggest breakthrough is our increasing ability to edit genes with a growing number of new classes of gene editing tools. This advance has led to the boom of CAR T products and is opening the path to cell engineering and in vivo gene therapy.

In parallel, we are seeing an evolution from viral delivery to alternatives with growing payload capacity. This will, as we are already seeing, lead to cures in diseases where that was unthinkable before!

Cell and gene therapies are at the forefront of innovation and transforming how we treat and potentially cure certain diseases. Cell and gene therapies(CGTs) have the potential to treat severe diseases, such as cancer, as well as rare diseases. Several such therapies are now on the market, including a treatment for an inherited retinal disease that causes blindness. That particular CGT represents an important medical milestone because it was the first curative gene therapy approved for use. Personally, I was excited and humbled at the same time to have been the Global Head bringing this transformational therapy to patients around the world. Many other CGTs are now in development and hopefully will lead to an expansion of the still-limited treatment options available to many patients and transform the clinical paradigm.

An important breakthrough? The demonstration that gain-of-function genetically weaponized somatic cells are potent pharmaceuticals in their own right: living synthetic therapeutics (LSTs).Case in point, after a quarter century of work with TILs and LAKs struggling to meet utilitarian endpoints, enter gain-of-function CAR engineering, and thus history is made.The same paradigm of cell gain-of-function genetic enhancement can readily be applied to alternate somatic cell platforms think MSCs and iPSCs with a limitless potential to improve clinical outcomes for acute and chronic ailments.

Id like to emphasize three milestones. First, the commercialization of gene therapies in general. The efficacy and safety have improved a lot since the 1990s.

Secondly, the explosion of immunotherapies. Onco-hematology has become a major opportunity for patients with otherwise lethal blood cancers.

Finally, the advances in gene editing technologies. These have opened the door to new therapies which we would have considered utterly incredible a few years ago.

The recent approval for Yescarta in second-line (2L) relapsed/refractory large B-cell lymphoma (LBCL) means that an order-of-magnitude more patients just became eligible for potentially curative therapies. One recent industry insight from Celltelligence suggested that moving from 3L to 2L will potentially double the targetable population in diffuse LBCL alone for CAR T cell therapy. As cell therapies move up the treatment paradigm and cell-based therapeutics are eventually approved to treat a range of cancers, the spotlight will turn (again) to manufacturing capacity. At Cellares, our belief is that high-throughput, end-to-end automation is set to revolutionize cell therapy manufacturing, allowing us to deliver more doses at lower cost to meet the demand. Its a truly exciting time for our industry!

The success of the CAR T cell therapy approach and how it has led to cures for childhood leukemias and lymphomas is an amazing story. Thanks to these incredible advances, kids who would no longer be here today are now effectively cured, and are going to live long, relatively healthy lives without suffering the long-term side effects of traditional chemotherapy and radiation. By allowing investigators to be highly creative in developing this approach, a fascinating new treatment process was developed, for both autologous and allogeneic CAR T cell therapies. Now, an entire industry has been born from utilizing patients and donors stem cells and a modified version of the AIDS virus to cure leukemia. This is truly a mind-blowing advancement that combines so many complex processes and biologics and really showcases the power of creative investigators to come up with amazing new treatment solutions.

See the original post:
The Biggest CGT Breakthroughs Through the Eyes of Our 2022 Power List - The Medicine Maker

Posted in Stem Cell Therapy | Comments Off on The Biggest CGT Breakthroughs Through the Eyes of Our 2022 Power List – The Medicine Maker